Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Raw Materials (2022 - 2026)

Ekso Bionics Holdings has reported Raw Materials over the past 4 years, most recently at $3.6 million for Q4 2025.

  • On a quarterly basis, Raw Materials rose 1.18% to $3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 1.18% increase, with the full-year FY2025 number at $3.6 million, up 1.18% from a year prior.
  • Raw Materials reached $3.6 million in Q4 2025 per EKSO's latest filing, down from $3.8 million in the prior quarter.
  • The five-year high for Raw Materials was $4.3 million in Q4 2023, with the low at $3.6 million in Q4 2024.
  • The 4-year median for Raw Materials is $4.0 million (2024), against an average of $3.9 million.
  • Peak YoY movement for Raw Materials: rose 12.01% in 2023, then dropped 17.38% in 2024.
  • Tracing EKSO's Raw Materials over 4 years: stood at $3.8 million in 2022, then grew by 12.01% to $4.3 million in 2023, then dropped by 17.38% to $3.6 million in 2024, then rose by 1.18% to $3.6 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $3.6 million, $3.8 million, and $4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.